Several other equities research analysts also recently weighed in on CBPO. Zacks Investment Research downgraded China Biologic Products from a hold rating to a sell rating in a report on Thursday, August 15th. ValuEngine downgraded China Biologic Products from a buy rating to a hold rating in a report on Wednesday, September 4th. Two research analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. China Biologic Products currently has an average rating of Hold and an average price target of $78.00.
Shares of CBPO traded up $0.09 during mid-day trading on Tuesday, reaching $100.05. 17,088 shares of the company’s stock were exchanged, compared to its average volume of 120,326. The stock has a market capitalization of $3.94 billion, a PE ratio of 24.89, a price-to-earnings-growth ratio of 6.08 and a beta of 1.18. The business’s fifty day simple moving average is $98.19 and its 200-day simple moving average is $93.52. China Biologic Products has a 52-week low of $60.08 and a 52-week high of $103.50.
A number of institutional investors have recently added to or reduced their stakes in the business. York Capital Management Global Advisors LLC lifted its holdings in China Biologic Products by 13.9% in the second quarter. York Capital Management Global Advisors LLC now owns 1,128,717 shares of the biopharmaceutical company’s stock valued at $107,567,000 after acquiring an additional 137,484 shares during the period. Vanguard Group Inc. increased its position in China Biologic Products by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 950,421 shares of the biopharmaceutical company’s stock worth $90,575,000 after purchasing an additional 29,178 shares in the last quarter. FIL Ltd increased its position in China Biologic Products by 1.8% during the 1st quarter. FIL Ltd now owns 519,071 shares of the biopharmaceutical company’s stock worth $47,365,000 after purchasing an additional 8,929 shares in the last quarter. Greenwoods Asset Management Ltd grew its holdings in China Biologic Products by 281.8% in the 1st quarter. Greenwoods Asset Management Ltd now owns 479,580 shares of the biopharmaceutical company’s stock valued at $43,762,000 after buying an additional 353,980 shares during the period. Finally, Maso Capital Partners Ltd grew its holdings in China Biologic Products by 3.3% in the 1st quarter. Maso Capital Partners Ltd now owns 164,500 shares of the biopharmaceutical company’s stock valued at $15,011,000 after buying an additional 5,300 shares during the period. 36.90% of the stock is owned by institutional investors.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
See Also: What is a short straddle?
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.